Join the Vantrela ER group to help and get support from people like you.
Vantrela ER News
FDA Requiring Stronger Safety Labels for Opioid Medications
MONDAY, Aug. 4, 2025 – The U.S. Food and Drug Administration announced it will now be requiring updated safety labels for all opioid pain medications to better highlight the risks of long-term use,...
FDA Medwatch Alert: FDA Requires Major Changes to Opioid Pain Medication Labeling to Emphasize Risks
July 31, 2025 – The U.S. Food and Drug Administration is requiring safety labeling changes to all opioid pain medications to better emphasize and explain the risks associated with their long-term...
Fewer Opioids Being Prescribed for Low Back Pain in the Emergency Department
FRIDAY, July 18, 2025 – From 2016 to 2022, 5.3 percent of all U.S. emergency department visits were related to low back pain, with opioid administration and prescription decreasing during this same...
Non-Opioids Can Ease Post-Dental Surgery Pain Better Than Opioids, Study Shows
THURSDAY, Jan. 9, 2025 – Over-the-counter (OTC) drugs acetaminophen and ibuprofen are better at managing dental pain than opioids. People who had their wisdom teeth removed got better results from...
FDA Medwatch Alert: Drug Safety Communication: All Opioid Pain Medicines - FDA Updates Prescribing Information to Provide Additional Guidance for Safe Use
ISSUE: The FDA is requiring several updates to the prescribing information for both immediate-release (IR) and extended release/long acting (ER/LA) opioid pain medicines. This includes stating for a...
Teva Receives FDA Approval for Vantrela ER (hydrocodone bitartrate) Extended-Release Tablets Formulated with Proprietary Abuse Deterrence Technology
JERUSALEM--(BUSINESS WIRE)--Jan. 18, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the U.S. Food and Drug Administration (FDA) approved Vantrela ER (hydrocodone...